Optic pathway glioma
Prepared with OnCo (onco.cc/prep/optic-pathway-glioma/). Orientation, not medical advice; your team knows your case.
My details
What I know, what is unclear, changes to discuss
Saved in this browserMy questions
9 on the sheet- 1.What is my exact diagnosis, stage, and grade, and which tests established them?
- 2.Which biomarkers have been tested on my tumour (for example Quantitative visual acuity, NF1 germline status, KIAA1549-BRAF fusion or BRAF V600E in sporadic tumours, MRI of the optic pathway and hypothalamus), and what were the results?
- 3.Which subtype is my cancer, and does that change the recommended treatment?
- 4.Is germline (inherited) genetic testing recommended for me or my family?
- 5.For my situation (stable vision), which of the standard options do you recommend and why?
- 6.For my situation (threatened vision or progression), which of the standard options do you recommend and why?
- 7.Am I a candidate for Carboplatin, Vincristine, Selumetinib or related drugs, and what side effects should I expect?
- 8.Would a second opinion at a high-volume centre change anything, and can you help arrange it?
- 9.What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?
Tests and results to bring
Biomarker results to ask for: Quantitative visual acuity (Teller cards, HOTV), NF1 germline status, KIAA1549-BRAF fusion or BRAF V600E in sporadic tumours, MRI of the optic pathway and hypothalamus.
Bring copies of scan reports, pathology and blood results, and a list of every medicine and supplement.
The treatments I may be offered
- Stable vision: Observation with ophthalmology and MRI follow-up. (Paediatric low-grade glioma)
- Threatened vision or progression: Carboplatin and vincristine, or selumetinib (phase 2, Fangusaro 2019), tovorafenib, or dabrafenib with trametinib for BRAF V600E; radiotherapy deferred. (Carboplatin, Vincristine, Selumetinib, Tovorafenib, Dabrafenib, Trametinib)
From the standard of care recorded for this cancer; which apply depends on your stage and biomarkers. Ask which the team recommends and why.